JERUSALEM, Israel, May 20, 2026
Scinai Immunotherapeutics Ltd. has announced the appointment of Eilon Elmalem as the new Site Head of its Yavne CDMO facility, marking a major operational milestone for the company’s expanding biopharmaceutical manufacturing platform. The appointment, effective June 14, 2026, was made through the company’s wholly owned subsidiary, Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO) supporting biotechnology and pharmaceutical companies worldwide.
The leadership transition comes as Scinai continues strengthening its position within the rapidly growing global CDMO market, where pharmaceutical outsourcing, biologics manufacturing, and GMP-compliant production capabilities are becoming increasingly critical to drug development and commercialization strategies. Company executives stated that Elmalem’s extensive operational, engineering, and manufacturing experience will support the continued expansion and operational excellence of the Yavne facility.
Scinai emphasized that the Yavne site plays an important role within its broader CDMO growth strategy, especially following the integration of operations acquired from Recipharm. The company believes the appointment will further accelerate infrastructure development, manufacturing scalability, and long-term commercial partnerships across the biotech sector.
Industry Veteran Brings Extensive GMP Manufacturing Expertise
Eilon Elmalem brings more than 20 years of experience across biotechnology, pharmaceutical manufacturing, engineering, process development, and industrial infrastructure management. Over the past two years, he has worked closely with Scinai as an external consultant, contributing to operational development initiatives and supporting transition planning for the Yavne facility.
Advertisement
Prior to joining Scinai in a permanent leadership role, Elmalem held senior executive positions at major life sciences organizations including Merck and Sigma-Aldrich Millipore, where he oversaw engineering, R&D, manufacturing, and operational activities across multiple international sites spanning Israel, Europe, and the United States. His background includes leadership of multidisciplinary teams, execution of large-scale organizational transformation projects, and oversight of major capital investment programs focused on advanced GMP manufacturing operations.
Scinai leadership noted that his expertise in process development, engineering integration, and facility expansion aligns closely with the company’s long-term strategy to expand high-quality biologics manufacturing services for pharmaceutical and biotechnology clients.
According to company officials, Elmalem will continue overseeing engineering activities while assuming full responsibility for site operations, ensuring continuity and operational efficiency as the Yavne facility scales its commercial manufacturing capabilities.
CDMO Expansion Reflects Growing Biopharma Outsourcing Demand
The global CDMO market continues experiencing rapid expansion as pharmaceutical and biotechnology companies increasingly outsource development and manufacturing activities to specialized partners capable of providing scalable, GMP-compliant infrastructure. Demand for biologics manufacturing, process optimization, and flexible production capacity has accelerated significantly due to rising therapeutic innovation across immunology, oncology, rare disease, and cell therapy markets.
Industry analysts believe experienced operational leadership has become increasingly important for CDMOs as manufacturers face growing regulatory expectations, quality assurance requirements, and pressure to accelerate production timelines for advanced therapeutics.
Scinai stated that the transition process officially began on May 10, 2026, under the supervision of current site head Dr. Sylvia Kachalsky, who will continue supporting the leadership transition before entering retirement leave later in the year. Company executives credited Dr. Kachalsky with playing a critical role in the successful operational integration of the Yavne facility into Scinai’s expanding CDMO network following the Recipharm acquisition.
Scinai Expands Biopharma Manufacturing and Immunology Focus
In addition to its CDMO operations, Scinai Immunotherapeutics continues advancing a pipeline of innovative immunology and inflammation-focused therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l. The company operates as both a clinical-stage biopharmaceutical innovator and a specialized manufacturing partner serving external biotechnology and pharmaceutical customers.
Healthcare industry experts believe companies capable of integrating therapeutic innovation with scalable manufacturing services may hold strategic advantages as biologics pipelines become increasingly complex and global demand for specialized production capacity continues rising.
Scinai’s ongoing investments in operational infrastructure, leadership development, and manufacturing integration reflect broader trends reshaping the global biopharmaceutical manufacturing sector. Analysts expect CDMOs with strong engineering expertise, regulatory compliance capabilities, and advanced biologics infrastructure to remain central players in supporting future pharmaceutical innovation and commercialization activities worldwide.
Source: Scinai Immunotherapeutics press release
